<DOC>
	<DOCNO>NCT02204982</DOCNO>
	<brief_summary>A study evaluate safety efficacy IPI 145 administer combination rituximab v placebo combination rituximab patient previously treat CD20-positive follicular lymphoma suitable candidate chemotherapy .</brief_summary>
	<brief_title>Study Duvelisib Combination With Rituximab v Rituximab Subjects With Previously Treated Follicular Lymphoma</brief_title>
	<detailed_description>Study IPI-145-08 international , multicenter , randomize , double-blind , placebo-controlled , parallel-group , Phase 3 study design evaluate efficacy safety IPI-145 combination rituximab v placebo combination rituximab subject previously treat CD20-positive follicular lymphoma . Approximately 400 subject receive 25 mg IPI-145 placebo , orally BID 28 day continuous cycle , combination 375 mg/m2 Rituximab give weekly 4 week Cycle 1 Day 1 Cycles 4 , 6 , 8 , 10 . Patients remain treatment 27 cycle may continue treatment clinical benefit observe .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis CD20positive FL : Histology grade 1 , 2 3a Biopsyconfirmed histopathological diagnosis FL . Biopsy specimen obtain ≤2 year prior randomization , unless medically contraindicate CD20 immunophenotyping perform ≤2 year prior randomization First subsequent relapse follow least one induction therapy regimen contain rituximab combination anthracycline rituximab combination alkylating agent Patients first relapse must chemoresistant intolerant chemotherapy No response disease progression ≤ 24 month start last previous therapy At least 1 measurable disease lesion &gt; 1.5 cm least one diameter CT/CTPET magnetic resonance imaging ( MRI ) area prior radiation therapy , area previously irradiate documented progression Clinical evidence indolent form lymphoma ( e.g. , marginal zone lymphoma [ MZL ] , small lymphocytic lymphoma [ SLL ] ) Transformation aggressive subtype lymphoma grade 3b FL Refractory rituximab : defined disease progression receive within 6 month complete either weekly rituximab induction therapy , rituximabbased chemoimmunotherapy induction Intolerance rituximab severe allergic anaphylactic reaction humanize murine monoclonal antibody Prior allogeneic hematopoietic stem cell transplant ( HSCT ) Known Central Nervous System ( CNS ) lymphoma ; subject symptoms CNS disease must negative CT scan negative diagnostic lumbar puncture Prior treatment PI3K inhibitor BTK inhibitor History tuberculosis within precede two year Ongoing systemic bacterial , fungal , viral infection randomization ( define require IV antimicrobial , antifungal antiviral agent ) Subjects antimicrobial , antifungal antiviral prophylaxis specifically exclude I/E criterion meet Prior , current , chronic hepatitis B hepatitis C infection , positive result hepatitis B surface antigen ( HBsAg ) hepatitis B core antibody ( HBcAb ) hepatitis C virus antibody ( HCV Ab ) History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Phase 3 , Follicular Lymphoma , FL , PI3K</keyword>
</DOC>